[
  {
    "ts": null,
    "headline": "BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets",
    "summary": "We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Novavax, Inc. stands second on our list of high growth stocks. TheFly reported on January 20 that BofA raised its price target on NVAX to $7 from $6 while maintaining an Underperform rating. The update followed the company’s announcement […]",
    "url": "https://finnhub.io/api/news?id=9ad23272df7a68107143cc02cecfad80b7d443bf1d252cb432942253fcc16742",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769864298,
      "headline": "BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets",
      "id": 138315130,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Novavax, Inc. stands second on our list of high growth stocks. TheFly reported on January 20 that BofA raised its price target on NVAX to $7 from $6 while maintaining an Underperform rating. The update followed the company’s announcement […]",
      "url": "https://finnhub.io/api/news?id=9ad23272df7a68107143cc02cecfad80b7d443bf1d252cb432942253fcc16742"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Raises Pfizer (PFE) PT to $27 Amid Shifting Obesity Data Focus",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald raised the firm’s price target on Pfizer to $27 from $24 and maintained a Neutral rating on the shares. With 2026 guidance already established and only modest beat-and-raise potential anticipated, the firm expects a […]",
    "url": "https://finnhub.io/api/news?id=31f94aebd734852080f7638b959a0427d1c07bfcb15a9134d687733bbddce137",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769863768,
      "headline": "Cantor Fitzgerald Raises Pfizer (PFE) PT to $27 Amid Shifting Obesity Data Focus",
      "id": 138315164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald raised the firm’s price target on Pfizer to $27 from $24 and maintained a Neutral rating on the shares. With 2026 guidance already established and only modest beat-and-raise potential anticipated, the firm expects a […]",
      "url": "https://finnhub.io/api/news?id=31f94aebd734852080f7638b959a0427d1c07bfcb15a9134d687733bbddce137"
    }
  },
  {
    "ts": null,
    "headline": "Alphabet, Amazon, AMD Lead Earnings Wave; Jobs Data On Deck",
    "summary": "Wall Street Week Ahead: key earnings (Amazon, Alphabet), IPOs, dividends & economic data (NFP, PMI). Read here for more details.",
    "url": "https://finnhub.io/api/news?id=b3e63802df6853657bf27d4f27978ea3f127e889b8b510bff3c097715be8804b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769857200,
      "headline": "Alphabet, Amazon, AMD Lead Earnings Wave; Jobs Data On Deck",
      "id": 138315868,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Wall Street Week Ahead: key earnings (Amazon, Alphabet), IPOs, dividends & economic data (NFP, PMI). Read here for more details.",
      "url": "https://finnhub.io/api/news?id=b3e63802df6853657bf27d4f27978ea3f127e889b8b510bff3c097715be8804b"
    }
  },
  {
    "ts": null,
    "headline": "The DGI Core Portfolio: 2025 Year-End Review",
    "summary": "The DGI Core Portfolio: 2025 Year-End Review",
    "url": "https://finnhub.io/api/news?id=e38a9974b47fdf124d7722526fb6b47b07c252956c3234c64c67d2b489b06471",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769847300,
      "headline": "The DGI Core Portfolio: 2025 Year-End Review",
      "id": 138314876,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e38a9974b47fdf124d7722526fb6b47b07c252956c3234c64c67d2b489b06471"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts",
    "summary": "Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and bezuclastinib in gastrointestinal cancer. Pfizer agreed to provide significant drug discounts under the U.S. government’s TrumpRx initiative. Management is refocusing R&D and capital toward oncology and obesity through targeted investments and acquisitions. For investors watching NYSE:PFE, these...",
    "url": "https://finnhub.io/api/news?id=a571de868bd25a59eca9f11692beffd9c1088b39cabd244a426cc9612fdf76b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769836155,
      "headline": "Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts",
      "id": 138313029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and bezuclastinib in gastrointestinal cancer. Pfizer agreed to provide significant drug discounts under the U.S. government’s TrumpRx initiative. Management is refocusing R&D and capital toward oncology and obesity through targeted investments and acquisitions. For investors watching NYSE:PFE, these...",
      "url": "https://finnhub.io/api/news?id=a571de868bd25a59eca9f11692beffd9c1088b39cabd244a426cc9612fdf76b5"
    }
  },
  {
    "ts": null,
    "headline": "5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill",
    "summary": "VZ, MO, PFE, KEY, and RF offer 4.2%+ yields as growing payouts rival Treasury bonds across banks and REITs. Learn why these stocks offer safe income in 2026.",
    "url": "https://finnhub.io/api/news?id=e7de25f61c7789600bfbad9e52930c1e6a7d260142fccfb66974bf5b81e27610",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769831238,
      "headline": "5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill",
      "id": 138313771,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1674657566/image_1674657566.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "VZ, MO, PFE, KEY, and RF offer 4.2%+ yields as growing payouts rival Treasury bonds across banks and REITs. Learn why these stocks offer safe income in 2026.",
      "url": "https://finnhub.io/api/news?id=e7de25f61c7789600bfbad9e52930c1e6a7d260142fccfb66974bf5b81e27610"
    }
  }
]